Cargando…

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins

Detalles Bibliográficos
Autores principales:	Blaeschke, Franziska, Stenger, Dana, Apfelbeck, Antonia, Cadilha, Bruno L., Benmebarek, Mohamed-Reda, Mahdawi, Jasmin, Ortner, Eva, Lepenies, Mareike, Habjan, Nicola, Rataj, Felicitas, Willier, Semjon, Kaeuferle, Theresa, Majzner, Robbie G., Busch, Dirk H., Kobold, Sebastian, Feuchtinger, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178409/ https://www.ncbi.nlm.nih.gov/pubmed/34088894 http://dx.doi.org/10.1038/s41408-021-00499-z

Ejemplares similares

Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function
por: Blaeschke, Franziska, et al.
Publicado: (2022)

Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation
por: Kaeuferle, Theresa, et al.
Publicado: (2019)

Genome‐wide off‐target analyses of CRISPR/Cas9‐mediated T‐cell receptor engineering in primary human T cells
por: Kaeuferle, Theresa, et al.
Publicado: (2022)

Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells
por: Willier, Semjon, et al.
Publicado: (2020)

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma
por: Rataj, Felicitas, et al.
Publicado: (2018)

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
por: Rataj, Felicitas, et al.
Publicado: (2018)

Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study
por: Willier, Semjon, et al.
Publicado: (2019)

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
por: Lorenzini, Theo, et al.
Publicado: (2023)

PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models
por: Lesch, Stefanie, et al.
Publicado: (2022)

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells
por: Cordes, Nicole, et al.
Publicado: (2021)

T-cell responses against CD19(+) pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
por: Feucht, Judith, et al.
Publicado: (2016)

Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival
Publicado: (1994)

High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate
por: Ingle, Gladys S, et al.
Publicado: (2008)

Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation
por: Li, Yixin, et al.
Publicado: (2010)

The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota
por: Blake, Stephen J., et al.
Publicado: (2021)

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
por: Stoiber, Stefan, et al.
Publicado: (2019)

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2019)

Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes
por: Hu, Changyun, et al.
Publicado: (2013)

Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
por: Schultz, Liora, et al.
Publicado: (2020)

Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody
Publicado: (1995)

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
por: Shinoda, Koji, et al.
Publicado: (2023)

Endogenous glutamine is rate-limiting for anti-CD3 and anti-CD28 induced CD4(+) T-cell proliferation and glycolytic activity under hypoxia and normoxia
por: Wik, Jonas A., et al.
Publicado: (2022)

Long-Term Remission of Diabetes in NOD Mice Is Induced by Nondepleting Anti-CD4 and Anti-CD8 Antibodies
por: Yi, Zuoan, et al.
Publicado: (2012)

Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells
por: Fuh, Franklin K, et al.
Publicado: (2017)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Upregulation of neuroreceptors on CD4+ and CD8+ T cells promotes their anti-tumor function
por: de Aquino, Maria Teresa, et al.
Publicado: (2015)

Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody
por: Li, Ziduo, et al.
Publicado: (2020)

CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer
por: Zhu, Wenjie, et al.
Publicado: (2021)

Soluble CD93 as a Novel Biomarker in Asthma Exacerbation
por: Sigari, Naseh, et al.
Publicado: (2016)

Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells
por: Fan, Dongmei, et al.
Publicado: (2015)

Anti-CD43 Inhibition of T Cell Homing
por: McEvoy, Leslie M., et al.
Publicado: (1997)

Antitumor activity of an anti‐CD98 antibody
por: Hayes, Gregory M., et al.
Publicado: (2015)

The association of anti-CD74 antibody with spondyloarthropathies
por: Çolak, Seda, et al.
Publicado: (2022)

CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions
Publicado: (1996)

Single Cell Analysis of Blood Mononuclear Cells Stimulated Through Either LPS or Anti-CD3 and Anti-CD28
por: Lawlor, Nathan, et al.
Publicado: (2021)

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
por: Faber, Mary L., et al.
Publicado: (2023)

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p4n1hvg12aucr3khlnd2vbrqip